Table 2.

PLSS for the global RV and six segments of the RV in healthy control and PE patients with and without PH before and after treatment

PLSS (%)	Healthy control (n = 40)	PE without PH before treatment (n = 39)	PE with PH before treatment (n = 34)	PE without PH after treatment (n = 39)	PE with PH after treatment (n = 34)
Global	− 22.89 ± 7.17	− 18.67 ± 7.37△	− 12.37 ± 6.68△	− 21.65 ± 7.98	− 18.38 ± 7.83*
Basal free wall	− 29.89 ± 8.07	− 21.15 ± 8.39△	− 15.00 ± 8.69△	− 27.63 ± 10.39	− 25.41 ± 9.63*
Mid free wall	− 29.01 ± 7.43	− 19.09 ± 7.49△	− 13.96 ± 6.98△	− 26.16 ± 7.31	− 21.89 ± 7.81*
Apical free wall	− 25.51 ± 9.07	− 17.18 ± 7.07△	− 13.27 ± 6.63△	− 23.30 ± 8.55	− 21.15 ± 7.22*
Basal septum	− 21.02 ± 5.98	− 16.75 ± 8.89△	− 12.51 ± 6.98△	− 19.56 ± 7.58	− 17.72 ± 6.38*
Mid septum	− 20.35 ± 5.25	− 16.83 ± 7.04△	− 10.68 ± 5.67△	− 18.17 ± 6.85	− 16.28 ± 5.96*
Apical septum	− 19.59 ± 5.72	− 16.42 ± 4.51△	− 11.84 ± 7.98△	− 19.09 ± 8.21	− 16.79 ± 6.26*

Data are expressed as $\overline{x}\pm S$

RV right ventricular, PE pulmonary embolism, PH pulmonary hypertension, PLSS peak longitudinal systolic strain

Compared to control group, *P < 0.05, ^△P < 0.01